Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 1

Trial Profile

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 1

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Bradykinin (Primary) ; Nesiritide (Primary) ; Sacubitril/valsartan (Primary) ; Sitagliptin (Primary) ; Substance P (Primary) ; Valsartan (Primary)
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms Aim 1
  • Most Recent Events

    • 26 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 20 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top